ArticleInternational journal of clinical and experimental pathology2017
SiRNA-Cyp4a14 and diabetic nephropathy: silencing of Cyp4a14 by siRNA inhibits proliferation and fibrosis of mesangial cells.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 7 citations in OpenAlex.
- Sex Differences in Dietary-Induced Liver Steatosis and Insulin Receptor-Related Signaling in Aged Mice Lacking Serotonin Transporter.International journal of molecular sciences · 2026Article
- Small interfering RNA (siRNA) as a potential gene silencing strategy for diabetes and associated complications: challenges and future perspectives.Journal of diabetes and metabolic disorders · 2024Review
- Exosomes as Promising Nanostructures in Diabetes Mellitus: From Insulin Sensitivity to Ameliorating Diabetic Complications.International journal of nanomedicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic nephropathy (DN) is one of the most common complications of diabetes, which increases mortality of diabetic patients. In recent years, many studies have confirmed that patients with diabetes are often accompanied by lipid metabolism disorders. Peroxisome proliferator-activated receptor (PPARs) is known to play pivotal roles in the regulation of insulin signaling, glucose and lipid metabolism. Cyp4a14 was confirmed to be the PPARα-target marker genes. We attempt to explore the biological role of Cyp4a14 in diabetic nephropathy. In our previous study, lncRNA microarray analysis showed us Cyp4a29-ps, Cyp4a14, Cyp4a12a and Cyp4a12b were the nearby mRNAs of lncRNA CYP4B1-PS1-001, we chose Cyp4a14 as our candidate. Renal cortical tissues were collected from db/db and db/m mice, and the mRNA expression of Cyp4a14 in diabetic tissue was significantly higher than that in normal tissue. And the expression of Cyp4a14 in mesangial cells cultured in high glucose was higher than that in low glucose by qualitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blot analysis. By Cell Counting Kit-8 (CCK8) and colony- forming ability, it is found that siRNA-Cyp4a14 treatment effectively suppressed the proliferation of mesangial cells. From our results, the protein expression of proliferating cell nuclear antigen (PCNA), Cyclin D1, Collagen I, and Fibronectin were all regulated dramatically in siRNA-Cyp4a14 group compared with the negative control group. Our data indicated that siRNA-Cyp4a14 inhibits proliferation and fibrosis of mesangial cells, which can be considered as a therapeutic target for diabetic nephropathy.
Indexed as
Identifiers
31966555PMC6966019W3009259374What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.